Form 8-K/A - Current report: [Amend]
SEC Accession No. 0001437749-24-030345
Filing Date
2024-10-01
Accepted
2024-10-01 16:07:35
Documents
15
Period of Report
2024-09-06
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K/A sava20240930_8ka.htm   iXBRL 8-K/A 29440
2 EXHIBIT 10.1 ex_728679.htm EX-10.1 56268
  Complete submission text file 0001437749-24-030345.txt   241121

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA sava-20240906.xsd EX-101.SCH 3409
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE sava-20240906_def.xml EX-101.DEF 12175
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE sava-20240906_lab.xml EX-101.LAB 16369
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE sava-20240906_pre.xml EX-101.PRE 12445
17 EXTRACTED XBRL INSTANCE DOCUMENT sava20240930_8ka_htm.xml XML 3109
Mailing Address 6801 N CAPITAL OF TEXAS HIGHWAY BUILDING 1; SUITE 300 AUSTIN TX 78731
Business Address 6801 N CAPITAL OF TEXAS HIGHWAY BUILDING 1; SUITE 300 AUSTIN TX 78731 512-501-2444
CASSAVA SCIENCES INC (Filer) CIK: 0001069530 (see all company filings)

EIN.: 911911336 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K/A | Act: 34 | File No.: 001-41905 | Film No.: 241343295
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)